Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Protection of study subjects

Executive Summary

FDA issues a draft guidance specifying the responsibilities investigators have to protect the rights and safety of patients participating in clinical trials. FDA says the agency became increasingly aware that current guidance and regulation - codified primarily in the 1970s - did not adequately address the increasing complexity of the modern clinical enterprise, including outsourcing. Comments are due by July 9...

You may also be interested in...



England’s NICE Recommends BMS/Celgene’s Revlimid For Follicular Lymphoma

Health technology assessment body NICE says that Revlimid fights cancer cells in a different way to current treatments which should help reduce resistance and improve disease outcomes.

Biogen Doubles Down On Alzheimer’s and Neuroscience With Sangamo Gene Regulation Deal

As sector awaits its aducanumab filing with bated breath, Biogen invests again in early stage neuroscience.

C-Suite Snippets: Growth Of A Cell And Gene Powerhouse

In case you missed it: catch up with snippets from interviews with industry leaders recently published by In Vivo.

UsernamePublicRestriction

Register

PS048479

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel